163 related articles for article (PubMed ID: 35965291)
1. Hetero-bivalent agents targeting FAP and PSMA.
Boinapally S; Lisok A; Lofland G; Minn I; Yan Y; Jiang Z; Shin MJ; Merino VF; Zheng L; Brayton C; Pomper MG; Banerjee SR
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4369-4381. PubMed ID: 35965291
[TBL] [Abstract][Full Text] [Related]
2. Radiochemistry and In Vivo Imaging of [
Saini S; Mullen GED; Blower PJ; Lapi SE
Mol Pharm; 2024 Feb; 21(2):822-830. PubMed ID: 38173242
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of a New Series of Albumin-Binding
Boinapally S; Alati S; Jiang Z; Yan Y; Lisok A; Singh R; Lofland G; Minn I; Hobbs RF; Pomper MG; Banerjee SR
Molecules; 2023 Aug; 28(16):. PubMed ID: 37630410
[TBL] [Abstract][Full Text] [Related]
4. PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [
Lu Q; Long Y; Fan K; Shen Z; Gai Y; Liu Q; Jiang D; Cai W; Wan C; Lan X
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4000-4013. PubMed ID: 35763056
[TBL] [Abstract][Full Text] [Related]
5. Development of [
Wen X; Xu P; Zeng X; Liu J; Du C; Zeng X; Cheng X; Wang X; Liang Y; Zhao T; Yang H; Li H; Meng L; Fang J; Liu H; Zhou Z; Zhang J; Zhang X; Guo Z; Chen X
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2846-2860. PubMed ID: 37097443
[TBL] [Abstract][Full Text] [Related]
6. ⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer.
Banerjee SR; Pullambhatla M; Foss CA; Nimmagadda S; Ferdani R; Anderson CJ; Mease RC; Pomper MG
J Med Chem; 2014 Mar; 57(6):2657-69. PubMed ID: 24533799
[TBL] [Abstract][Full Text] [Related]
7. Improving Theranostic Gallium-68/Lutetium-177-Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer.
Lee BS; Kim MH; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim HS; Kim MH; Kil HS; Han SJ; Lee YJ; Lee KC; Lim SM; Chi DY
Mol Cancer Ther; 2021 Dec; 20(12):2410-2419. PubMed ID: 34725194
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Preclinical Evaluation of Two Novel
Verena A; Merkens H; Chen CC; Chapple DE; Wang L; Bendre S; Wong AAWL; Bénard F; Lin KS
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398552
[TBL] [Abstract][Full Text] [Related]
9. Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer.
Meher N; Ashley GW; Bobba KN; Wadhwa A; Bidkar AP; Dasari C; Mu C; Sankaranarayanan RA; Serrano JAC; Raveendran A; Bulkley DP; Aggarwal R; Greenland NY; Oskowitz A; Wilson DM; Seo Y; Santi DV; VanBrocklin HF; Flavell RR
Adv Healthc Mater; 2024 May; ():e2304618. PubMed ID: 38700450
[TBL] [Abstract][Full Text] [Related]
10. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.
Yang T; Peng L; Qiu J; He X; Zhang D; Wu R; Liu J; Zhang X; Zha Z
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2331-2341. PubMed ID: 36864362
[TBL] [Abstract][Full Text] [Related]
11. Development and Preclinical Evaluation of [
El Fakiri M; Ayada N; Müller M; Hvass L; Gamzov TH; Clausen AS; Geis NM; Steinacker N; Hansson E; Lindegren S; Aneheim E; Jensen H; Eder AC; Jensen AI; Poulie CBM; Kjaer A; Eder M; Herth MM
J Nucl Med; 2024 Apr; 65(4):593-599. PubMed ID: 38423784
[TBL] [Abstract][Full Text] [Related]
12. Prostate-Specific Membrane Antigen Targeted Deep Tumor Penetration of Polymer Nanocarriers.
Meher N; Ashley GW; Bidkar AP; Dhrona S; Fong C; Fontaine SD; Beckford Vera DR; Wilson DM; Seo Y; Santi DV; VanBrocklin HF; Flavell RR
ACS Appl Mater Interfaces; 2022 Nov; 14(45):50569-50582. PubMed ID: 36318757
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Evaluation of a Novel High-Affinity Radioligand [
Bezverkhniaia E; Kanellopoulos P; Abouzayed A; Larkina M; Oroujeni M; Vorobyeva A; Rosenström U; Tolmachev V; Orlova A
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139219
[TBL] [Abstract][Full Text] [Related]
14. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
Pang Y; Zhao L; Fang J; Chen J; Meng L; Sun L; Wu H; Guo Z; Lin Q; Chen H
J Nucl Med; 2023 Sep; 64(9):1449-1455. PubMed ID: 37321827
[TBL] [Abstract][Full Text] [Related]
15. An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy.
Xu M; Chen J; Zhang P; Cai J; Song H; Li Z; Liu Z
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3214-3224. PubMed ID: 37318538
[TBL] [Abstract][Full Text] [Related]
16. Mono- and multimeric PSMA-targeting small molecule-thorium-227 conjugates for optimized efficacy and biodistribution in preclinical models.
Böhnke N; Indrevoll B; Hammer S; Papple A; Kristian A; Briem H; Celik A; Mumberg D; Cuthbertson A; Zitzmann-Kolbe S
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):669-680. PubMed ID: 37882848
[TBL] [Abstract][Full Text] [Related]
17. Development, preclinical evaluation and preliminary dosimetry profiling of SB03178, a first-of-its-kind benzo[h]quinoline-based fibroblast activation protein-α-targeted radiotheranostic for cancer imaging and therapy.
Bendre S; Merkens H; Kuo HT; Ng P; Wong AAWL; Lau WS; Zhang Z; Kurkowska S; Chen CC; Uribe C; Bénard F; Lin KS
Eur J Med Chem; 2024 Mar; 268():116238. PubMed ID: 38367492
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Effects of DOTA and NOTA Chelators on
Lee I; Kim MH; Lee K; Oh K; Lim H; Ahn JH; Lee YJ; Cheon GJ; Chi DY; Lim SM
Diagnostics (Basel); 2023 Aug; 13(16):. PubMed ID: 37627908
[TBL] [Abstract][Full Text] [Related]
19. Lu-177-Labeled Hetero-Bivalent Agents Targeting PSMA and Bone Metastases for Radionuclide Therapy.
Zha Z; Ploessl K; Choi SR; Zhao R; Jin W; Wang R; Alexoff D; Zhu L; Kung HF
J Med Chem; 2023 Sep; 66(17):12602-12613. PubMed ID: 37670407
[TBL] [Abstract][Full Text] [Related]
20. Radiotheranostics Using a Novel
Iikuni S; Tarumizu Y; Nakashima K; Higaki Y; Ichikawa H; Watanabe H; Ono M
J Med Chem; 2021 Sep; 64(18):13429-13438. PubMed ID: 34477385
[No Abstract] [Full Text] [Related]
[Next] [New Search]
